- Home
- BLX vs HCM Comparison
BLX vs HCM Comparison
Compare BLX & HCM Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Company Overview
Basic Information| Metric | BLX | HCM |
|---|---|---|
| Founded | 1977 | 2000 |
| Country | Panama | Hong Kong |
| Employees | N/A | 1796 |
| Industry | Commercial Banks | Biotechnology: Pharmaceutical Preparations |
| Sector | Finance | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 2.1B | 2.3B |
| IPO Year | 1997 | N/A |
Fundamental Metrics
Financial Performance| Metric | BLX | HCM |
|---|---|---|
| Price | $61.42 | $10.78 |
| Analyst Decision | | Sell |
| Analyst Count | 0 | 1 |
| Target Price | N/A | ★ $13.75 |
| AVG Volume (30 Days) | ★ 198.6K | 54.0K |
| Earning Date | 04-27-2026 | 03-05-2026 |
| Dividend Yield | ★ 5.13% | N/A |
| EPS Growth | N/A | N/A |
| EPS | N/A | N/A |
| Revenue | N/A | N/A |
| Revenue This Year | $18.36 | $20.60 |
| Revenue Next Year | $9.95 | $15.62 |
| P/E Ratio | $8.26 | ★ $5.49 |
| Revenue Growth | N/A | N/A |
| 52 Week Low | $38.41 | $9.77 |
| 52 Week High | $63.17 | $19.50 |
Technical Indicators
Market Signals| Indicator | BLX | HCM |
|---|---|---|
| Relative Strength Index (RSI) | 64.40 | 46.60 |
| Support Level | $43.50 | $9.77 |
| Resistance Level | N/A | $15.75 |
| Average True Range (ATR) | 1.69 | 0.27 |
| MACD | 0.05 | 0.14 |
| Stochastic Oscillator | 68.19 | 83.46 |
Price Performance
Historical ComparisonAbout BLX Banco Latinoamericano de Comercio Exterior S.A.
Banco Latinoamericano de Comercio Exterior SA provides financial solutions to financial institutions, companies, and investors doing business in Latin America, supporting trade and regional integration. The Bank provides foreign trade solutions to a select client base of American financial institutions and corporations and has developed a network of correspondent banking institutions with access to the international capital markets. It has two business segments: the Commercial Business Segment and the Treasury Business Segment. The majority of its revenue is generated from the Commercial Business segment.
About HCM HUTCHMED (China) Limited
HUTCHMED (China) Ltd is a biopharmaceutical company engaged in the discovery, development, and commercialization of targeted therapies and immunotherapies for the treatment of cancer and immunological diseases. The company has a portfolio of several cancer drug candidates currently in clinical studies world-wide and an extensive commercial infrastructure in its home market, China. The company operates in two reportable segments: Oncology/Immunology and Other Ventures.